Dually Enzyme- and Acid-Triggered Self-Immolative Ketal Glycoside Nanoparticles for Effective Cancer Prodrug Monotherapy.
暂无分享,去创建一个
Xing-jie Liang | D. Kohane | T. Ji | Shutao Guo | N. Gong | J. Chen | Tao Liu | Na Yu | Xi Zhang
[1] D. Kohane,et al. Light-triggered release of conventional local anesthetics from a macromolecular prodrug for on-demand local anesthesia , 2020, Nature Communications.
[2] Xing-jie Liang,et al. Modular Acid-Activatable Acetone-Based Ketal-Linked Nanomedicine by Dexamethasone Prodrugs for Enhanced Anti-Rheumatoid Arthritis with Low Side Effects. , 2020, Nano letters.
[3] Beob Soo Kim,et al. Systemic Brain Delivery of Antisense Oligonucleotides across the Blood–Brain Barrier with a Glucose‐Coated Polymeric Nanocarrier , 2020, Angewandte Chemie.
[4] Shutao Guo,et al. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy. , 2020, Biomacromolecules.
[5] Jianxun Ding,et al. Editorial: Applications of Nanobiotechnology in Pharmacology , 2019, Front. Pharmacol..
[6] Gangliang Huang,et al. Application of glycosylation in targeted drug delivery. , 2019, European journal of medicinal chemistry.
[7] Fabian Kiessling,et al. Smart cancer nanomedicine , 2019, Nature Nanotechnology.
[8] Qiang Zhao,et al. Upconversion-like Photolysis of BODIPY-Based Prodrugs via a One-Photon Process. , 2019, Journal of the American Chemical Society.
[9] D. Kohane,et al. Polymer-tetrodotoxin conjugates to induce prolonged duration local anesthesia with minimal toxicity , 2019, Nature Communications.
[10] Junqing Wang,et al. Nanobuffering of pH-Responsive Polymers: A Known but Sometimes Overlooked Phenomenon and Its Biological Applications. , 2019, ACS nano.
[11] O. Farokhzad,et al. Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy. , 2018, ACS nano.
[12] O. Farokhzad,et al. Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. , 2018, Nano letters.
[13] Fabian Kiessling,et al. Tumor targeting via EPR: Strategies to enhance patient responses. , 2018, Advanced drug delivery reviews.
[14] N. Meanwell,et al. The expanding role of prodrugs in contemporary drug design and development , 2018, Nature Reviews Drug Discovery.
[15] Weijian Chen,et al. Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy. , 2017, Nano letters.
[16] Feng Li,et al. Lipid-Drug Conjugate for Enhancing Drug Delivery. , 2017, Molecular pharmaceutics.
[17] S. Lippard,et al. Chemical Approach to Positional Isomers of Glucose-Platinum Conjugates Reveals Specific Cancer Targeting through Glucose-Transporter-Mediated Uptake in Vitro and in Vivo. , 2016, Journal of the American Chemical Society.
[18] Kristofer J. Thurecht,et al. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.
[19] D. Kohane,et al. Extended Release of Native Drug Conjugated in Polyketal Microparticles. , 2016, Journal of the American Chemical Society.
[20] S. Lippard,et al. A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells. , 2016, Angewandte Chemie.
[21] Ahmed Alouane,et al. Self-immolative spacers: kinetic aspects, structure-property relationships, and applications. , 2015, Angewandte Chemie.
[22] Y. Ni,et al. Relationship Between 18F-FDG Accumulation and Lactate Dehydrogenase A Expression in Lung Adenocarcinomas , 2014, The Journal of Nuclear Medicine.
[23] F. Liu,et al. Disulfide Bond Bridge Insertion Turns Hydrophobic Anticancer Prodrugs into Self-Assembled Nanomedicines , 2014, Nano letters.
[24] Martin G Pomper,et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[25] T. Nakajima,et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. , 2014, Lung cancer.
[26] Paul J Hergenrother,et al. Glucose conjugation for the specific targeting and treatment of cancer. , 2013, Chemical science.
[27] P. Couvreur,et al. Squalenoylation: a generic platform for nanoparticular drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[28] D. Leigh,et al. Rotaxane-based propeptides: protection and enzymatic release of a bioactive pentapeptide. , 2009, Angewandte Chemie.
[29] A. V. Pavlovsky,et al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. , 2009, European journal of cancer.
[30] P. Couvreur,et al. Squalenoyl nanomedicines as potential therapeutics. , 2006, Nano letters.
[31] L. Tietze,et al. Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy. , 2006, Angewandte Chemie.
[32] A new paclitaxel prodrug for use in ADEPT strategy. , 2003, Organic & biomolecular chemistry.
[33] J. Backman,et al. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. , 2002, The Journal of pharmacology and experimental therapeutics.
[34] H. W. Scheeren,et al. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. , 2001, Current medicinal chemistry.
[35] H. Haisma,et al. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer , 2001, British Journal of Cancer.
[36] C. Monneret,et al. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. , 1998, Journal of medicinal chemistry.
[37] J. Backman,et al. The Role of β-Glucuronidase in Drug Disposition and Drug Targeting in Humans , 1997 .
[38] M. Beller,et al. Development of Tailor-Made Cytostatics Activable by Acid-Catalyzed Hydrolysis for Selective Tumor Therapy† , 1990 .